Amgen to buy Turkish drugmaker for $700 million

LONDON (Reuters) – U.S. biotech company Amgen is to buy Turkey’s Mustafa Nevzat Pharmaceuticals, a maker of injectable generic drugs, for around $700 million in a deal underscoring Western drugmakers’ thirst for emerging markets sales. The purchase, announced by both companies on Wednesday, is the latest in a string of acquisitions by international drug companies – both at home and abroad – as they try to buy growth to offset patent expiries and price cuts. …